¼¼°èÀÇ È¯ÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ½ÃÀå
Patient Generated Health Data
»óǰÄÚµå : 1794602
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 277 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 75¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 52¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 75¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÇÆ®´Ï½º ¹× À£´Ï½º µ¥ÀÌÅÍ´Â CAGR 8.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 33¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áúº´ °ü¸® µ¥ÀÌÅÍ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 14¾ï ´Þ·¯, Áß±¹Àº CAGR 10.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ È¯ÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀº 2024³â¿¡ 14¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 16¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.9%¿Í 6.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ È¯ÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅͶõ ¹«¾ùÀ̸ç, ¿Ö ÀÓ»óÀû ÀÇ»ç°áÁ¤¿¡ À¯¿ëÇѰ¡?

ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ(PGHD)´Â ¿þ¾î·¯ºí, ¸ð¹ÙÀÏ ¾Û, ÀÚ°¡º¸°í ÀÔ·Â µî ±âÁ¸ ÀÓ»ó ÇöÀå ¿Ü¿¡¼­ °³ÀÎÀÌ »ý¼º, ±â·Ï, ¼öÁýÇÑ °Ç°­ °ü·Ã µ¥ÀÌÅ͸¦ ¸»ÇÕ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ¿¡´Â Áõ»ó, »ýȰ½À°ü Çൿ, »ýü ÃøÁ¤°ª, Ä¡·á ¼øÀÀµµ, »îÀÇ Áú ÁöÇ¥¿¡ ´ëÇÑ Á¤º¸°¡ Æ÷ÇԵ˴ϴÙ. PGHD´Â º´¿ø ¹æ¹®À̳ª °Ë»ç¸¦ ÅëÇØ ¾òÀº µ¥ÀÌÅÍ¿Í ´Þ¸®, ȯÀÚÀÇ ÀÏ»óÀûÀÎ °Ç°­ »óÅ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ½Ç½Ã°£ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

PGHDÀÇ »ç¿ëÀº ƯÈ÷ ¸¸¼ºÁúȯ °ü¸®¿Í ¿¹¹æÀÇÇп¡¼­ ȯÀÚ ¸ð´ÏÅ͸µ°ú °³º°È­µÈ Ä¡·á Á¦°ø¿¡ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. PGHD´Â ÀÓ»ó°ú ÀÓ»ó »çÀÌÀÇ Áß¿äÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇϰí ÀÓ»óÀÇ¿¡°Ô ȯÀÚÀÇ °æ°ú¿Í Çൿ¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÎ ½Ã°¢À» Á¦°øÇÕ´Ï´Ù. ÇコÄɾ °á°ú ±â¹Ý ¸ðµ¨·Î ÀüȯµÇ°í ÀÖ´Â °¡¿îµ¥, PGHD¸¦ Äɾî Ç÷£¿¡ Æ÷ÇÔ½ÃÅ´À¸·Î½á ¹ÝÀÀ¼º, Á¶±â °³ÀÔ, ȯÀÚ¿Í ÀÇ·áÁø °£ÀÇ Çù·ÂÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

PGHDÀÇ ¼öÁý°ú »ç¿ëÀ» Áö¿øÇÏ´Â ÀåÄ¡, Ç÷§Æû, Ç¥ÁØÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀ¸·Î PGHDÀÇ ¹üÀ§, Á¤È®µµ, »ç¿ë ÆíÀǼºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ±â±â´Â ÇöÀç ½É¹Ú¼ö, Æ÷µµ´ç ¼öÄ¡, ¼ö¸é ÆÐÅÏ, Ȱµ¿·® µî ´Ù¾çÇÑ ¸Å°³º¯¼ö¸¦ ÀÇ·á ¼öÁØÀÇ Á¤È®µµ·Î ¸ð´ÏÅ͸µÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ®Æù ¾ÖÇø®ÄÉÀ̼ÇÀ» ÅëÇØ »ç¿ëÀÚ´Â ¾à¹° ¼·Ãë·®, ±âºÐ, ½Ä½À°ü µîÀ» ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. À½¼º ÀÎ½Ä µµ±¸¿Í ½º¸¶Æ®È¨ µð¹ÙÀ̽ºµµ ȯÀÚ°¡ »ç¿ëÇϱ⠽¬¿î ÇüÅ·Π¼öµ¿ÀûÀÎ µ¥ÀÌÅÍ ¼öÁý¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

PGHD¸¦ ÀÓ»óÀûÀ¸·Î ÀûÇÕÇÏ°Ô ¸¸µé±â À§ÇØ ÀÌ µ¥ÀÌÅ͸¦ ±¸Á¶È­µÇ°í ÇØ¼® °¡´ÉÇÑ Çü½ÄÀ¸·Î ÀüÀÚÀǹ«±â·Ï¿¡ ÅëÇÕÇϱâ À§ÇÑ Ç÷§ÆûÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. Ç¥ÁØÈ­µÈ API¿Í µ¥ÀÌÅÍ °Å¹ö³Í½º ÇÁ·¹ÀÓ¿öÅ©¸¦ ÅëÇØ µ¥ÀÌÅÍ º¸¾È, »óÈ£¿î¿ë¼º, µ¿ÀÇ °ü¸®°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó ¾Ë°í¸®Áò°ú ´ë½Ãº¸µå´Â Àǻ簡 PGHD¸¦ ÇÊÅ͸µ, ¿ì¼±¼øÀ§È­, ½Ã°¢È­ÇÏ¿© ¿ø½Ã µ¥ÀÌÅÍ¿¡ ¾Ðµµ´çÇÏÁö ¾Ê°í ÀÇ¹Ì ÀÖ´Â º¯È­¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

PGHDÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Â °÷Àº ¾îµðÀ̸ç, ¾î¶² »ç¿ë»ç·Ê°¡ ¾ÖÇø®ÄÉÀ̼ÇÀ» ÁÖµµÇϰí Àִ°¡?

PGHD´Â ÇコÄÉ¾î ½Ã½ºÅÛ, À£´Ï½º ÇÁ·Î±×·¥, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼­ºñ½º, ÀÓ»ó ¿¬±¸ µî¿¡ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´Àº ȯÀÚ ÁÖµµÇü µ¥ÀÌÅÍ È°¿ëÀ» À§ÇÑ ÀÎÇÁ¶ó Áغñ¿Í ±ÔÁ¦Àû Áö¿ø¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿þ¾î·¯ºí°ú °Ç°­ ¾ÛÀÇ °¡°ÝÀÌ Àú·ÅÇØÁö°í ´Ù¾çÇÑ °èÃþÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ ºü¸£°Ô Ãß°ÝÇϰí ÀÖ½À´Ï´Ù.

»ç¿ë »ç·Ê´Â ´ç´¢º´, ½ÉÇ÷°üÁúȯ, Á¤½Å°Ç°­, Á¾¾çÇÐ, È£Èí±âÁúȯ µî ´Ù¾çÇÑ ÁúȯÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ÇÁ·Î±×·¥Àº PGHD¿¡ ÀÇÁ¸ÇÏ¿© Á¶±â °æ°í ¡Èĸ¦ °¨ÁöÇϰí ÀÔ¿øÀ» ÁÙÀ̱â À§ÇØ PGHD¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­ ȯÀÚ º¸°í °á°ú¿Í ½Ç½Ã°£ ¹ÙÀÌ¿À¸ÞÆ®¸¯À» ÅëÇØ µ¥ÀÌÅÍÀÇ Á¤È®¼º°ú Âü¿©ÀÚ À¯ÁöÀ²À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. º¸Çè»çµéµµ PGHD¸¦ Ȱ¿ëÇÏ¿© À£´Ï½º Àμ¾Æ¼ºê¸¦ Á¶Á¤Çϰí À§Çè ÇÁ·ÎÆÄÀÏÀ» º¸´Ù Á¤È®ÇÏ°Ô Æò°¡Çϰí ÀÖ½À´Ï´Ù.

ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù.

ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ ½ÃÀåÀÇ ¼ºÀåÀº ¿þ¾î·¯ºí ±â¼ú äÅà Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, Áö¼ÓÀûÀÎ °Ç°­ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¾¼­ÀÇ ¼ÒÇüÈ­, ¸ð¹ÙÀÏ ¿¬°á¼º, °Ç°­ ÃßÀû ¾Ë°í¸®ÁòÀÇ ¹ßÀüÀ¸·Î ´Ù¾çÇÑ °èÃþ¿¡¼­ ½Å·ÚÇÒ ¼ö ÀÖ°í »ç¿ëÇϱ⠽¬¿î µ¥ÀÌÅÍ ¼öÁýÀÌ °¡´ÉÇØÁ³½À´Ï´Ù.

¿ø°ÝÁø·á¿¡ ´ëÇÑ È¯±Þ°ú µðÁöÅÐ ÀÇ·á ±â·ÏÀÇ ÅëÇÕÀ» Áö¿øÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ ÀÏ»óÀûÀÎ Áø·á °ü¸®¿¡ PGHD¸¦ Æ÷ÇÔÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ ¸ð´ÏÅ͸µ, Åð¿ø ÈÄ °ü¸®, À£´Ï½º Æ®·¡Å·Àº PGHDÀÇ ½Ç¿ë¼ºÀÌ ³ôÀº ÀÀ¿ë ºÐ¾ß¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ȯÀÚµéÀÇ Àνİú ÀÚ±â°ü¸® ÇൿÀÇ Çâ»óÀ¸·Î µ¥ÀÌÅͰ¡ ´õ¿í dzºÎÇØÁö°í ÀÖÀ¸¸ç, PGHD´Â Áý´Ü °Ç°­ ºÐ¼®, À§Çè °èÃþÈ­, »çÀü ¿¹¹æÀû Ä¡·á Á¦°ø ¸ðµ¨¿¡ Áß¿äÇÑ ÀÎDzÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

µ¥ÀÌÅÍ À¯Çü(ÇÇÆ®´Ï½º ¹× À£´Ï½º µ¥ÀÌÅÍ, Áúº´ °ü¸® µ¥ÀÌÅÍ, ¿ø°Ý ¸ð´ÏÅ͸µ µ¥ÀÌÅÍ, ±âŸ µ¥ÀÌÅÍ À¯Çü), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¹× Ŭ¸®´Ð ÃÖÁ¾»ç¿ëÀÚ, ¿¬±¸ ¼¾ÅÍ ÃÖÁ¾»ç¿ëÀÚ, ÀÇ·áºñ ÁöºÒÀÚ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Patient Generated Health Data Market to Reach US$7.5 Billion by 2030

The global market for Patient Generated Health Data estimated at US$5.2 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Fitness & Wellness Data, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Disease Management Data segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 10.0% CAGR

The Patient Generated Health Data market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Patient Generated Health Data Market - Key Trends & Drivers Summarized

What Is Patient Generated Health Data and Why Is It Valuable in Clinical Decision Making?

Patient generated health data (PGHD) refers to health-related data created, recorded, or gathered by individuals outside traditional clinical settings, often through wearables, mobile apps, or self-reported inputs. This data includes information on symptoms, lifestyle behaviors, biometric readings, treatment adherence, and quality of life metrics. Unlike data captured during hospital visits or lab tests, PGHD provides continuous, real-time insights into a patient’s day-to-day health status.

The use of PGHD is transforming patient monitoring and personalized care delivery, particularly in chronic disease management and preventive health. It fills important gaps between clinical encounters, offering clinicians a more holistic view of patient progress and behavior. As healthcare moves toward outcome-based models, the inclusion of PGHD in care planning is improving responsiveness, early intervention, and patient-provider collaboration.

How Are Devices, Platforms, and Standards Evolving to Support PGHD Collection and Use?

Technological advancements are enhancing the scope, accuracy, and usability of PGHD. Wearable devices now monitor a wide range of parameters including heart rate, glucose levels, sleep patterns, and activity levels with medical-grade precision. Smartphone applications are allowing users to track medication intake, mood, and dietary habits. Voice recognition tools and smart home devices are also contributing to passive data capture in patient-friendly formats.

To make PGHD clinically relevant, platforms are being developed to integrate this data into electronic health records in structured, interpretable formats. Standardized APIs and data governance frameworks are improving data security, interoperability, and consent management. Clinical algorithms and dashboards are being designed to filter, prioritize, and visualize PGHD for physicians, enabling them to respond to meaningful changes without being overwhelmed by raw data.

Where Is PGHD Adoption Expanding and Which Use Cases Are Leading Application?

PGHD adoption is growing across healthcare systems, wellness programs, remote patient monitoring services, and clinical research. North America and Europe are leading in infrastructure readiness and regulatory support for patient-driven data use. Asia-Pacific is catching up rapidly as wearables and health apps become more affordable and accessible to broad segments of the population.

Use cases are expanding across conditions such as diabetes, cardiovascular disease, mental health, oncology, and respiratory illness. Remote patient monitoring programs rely on PGHD to detect early warning signs and reduce hospital admissions. In clinical trials, patient-reported outcomes and real-time biometrics are improving data accuracy and participant retention. Insurance providers are also utilizing PGHD to tailor wellness incentives and assess risk profiles with greater precision.

Growth in the Patient Generated Health Data market is driven by several factors…

Growth in the patient generated health data market is driven by factors such as rising adoption of wearable technologies, increasing focus on personalized medicine, and growing demand for continuous health monitoring. Advances in sensor miniaturization, mobile connectivity, and health tracking algorithms are enabling reliable, user-friendly data collection across varied demographics.

Regulatory frameworks supporting remote care reimbursement and digital health record integration are encouraging healthcare providers to include PGHD in routine care management. Chronic disease monitoring, post-discharge care, and wellness tracking are creating high-utility application areas for PGHD. Enhanced patient awareness and self-management behaviors are further contributing to data richness, making PGHD a key input for population health analytics, risk stratification, and proactive care delivery models.

SCOPE OF STUDY:

The report analyzes the Patient Generated Health Data market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Data Type (Fitness & Wellness Data, Disease Management Data, Remote Monitoring Data, Other Data Types); End-Use (Hospitals & Clinics End-Use, Research Centers End-Use, Healthcare Payers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â